



Novel Aspects in the Pathophysiology and Treatment of Diabetes Mellitus

Guest Editors:

Dr. Chrysi Koliaki

First Propaedeutic Department of
Internal Medicine and Diabetes
Center, National Kapodistrian
University of Athens, Laiko
University Hospital, 11527
Athens, Greece

**Prof. Dr. Nicholas
Katsilambros**

1. First Department of
Propaedeutic Medicine, National
Kapodistrian University of
Athens, Laiko University Hospital,
11527 Athens, Greece
2. Research Laboratory Christeas
Hall, Medical School, National
Kapodistrian University of
Athens, 11527 Athens, Greece

Message from the Guest Editors

The aim of this Special Issue is to provide a platform for sharing all the novel insights into the pathophysiology and treatment of diabetes mellitus. Both original research and comprehensive review articles on this topic are invited for submission. Papers on potential novel biomarkers for the prediction of diabetes and its complications (including the omics technology); pathophysiological concepts related to the mechanisms described above; and treatment strategies (medical nutrition, metabolic surgery, drugs, innovative approaches based on nanotechnology or artificial intelligence) in the context of precision diabetology are particularly welcome.

Deadline for manuscript
submissions:

closed (31 December 2022)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)